Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Accumulated Expenses for 16 consecutive years, with $33.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 5835.54% to $33.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.2 million through Dec 2025, up 5835.54% year-over-year, with the annual reading at $33.2 million for FY2025, 5835.54% up from the prior year.
  • Accumulated Expenses hit $33.2 million in Q4 2025 for Ironwood Pharmaceuticals, down from $34.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $34.6 million in Q3 2025 to a low of $560000.0 in Q4 2024.
  • Historically, Accumulated Expenses has averaged $13.6 million across 5 years, with a median of $9.4 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: plummeted 97.19% in 2024 and later soared 5835.54% in 2025.
  • Year by year, Accumulated Expenses stood at $16.7 million in 2021, then fell by 26.33% to $12.3 million in 2022, then soared by 62.51% to $19.9 million in 2023, then tumbled by 97.19% to $560000.0 in 2024, then skyrocketed by 5835.54% to $33.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for IRWD at $33.2 million in Q4 2025, $34.6 million in Q3 2025, and $24.0 million in Q2 2025.